Article
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
Blood - 4 May 2017
Xu Lian, Tsakmaklis Nicholas, Yang Guang, Chen Jiaji G, Liu Xia, Demos Maria, Kofides Amanda, Patterson Christopher J, Meid Kirsten, Gustine Joshua, Dubeau Toni, Palomba M Lia, Advani Ranjana, Castillo Jorge J, Furman Richard R, Hunter Zachary R, Treon Steven P
Abstract excerpt
Ibrutinib produces high response rates and durable remissions in Waldenström macroglobulinemia (WM) that are impacted by MYD88 and CXCR4WHIM mutations. Disease progression can develop on ibrutinib, although the molecular basis remains to be clarified. We sequenced sorted CD19+ lymphoplasmacytic cells from 6 WM patients who progressed after achieving major responses on ibrutinib using Sanger, TA cloning and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.